

# Jin Seok Ahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3774820/publications.pdf>

Version: 2024-02-01

254  
papers

7,669  
citations

61984

43  
h-index

76900

74  
g-index

258  
all docs

258  
docs citations

258  
times ranked

11414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285.	12.8	565
2	Alectinib in Crizotinib-Refractory <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	1.6	548
3	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	12.8	263
4	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495.	1.6	233
5	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666.	1.6	215
6	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 106-111.	1.1	203
7	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469.	2.4	156
8	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137
9	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016, 7, 6984-6993.	1.8	134
10	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2144-2154.	7.0	134
11	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725.	12.8	122
12	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	1.1	104
13	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47.	1.1	98
14	Incidence of Diabetes After Cancer Development. <i>JAMA Oncology</i> , 2018, 4, 1099.	7.1	96
15	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 255-266.	2.5	96
16	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	1.6	94
17	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	10.7	92
18	A Dramatic Response to Crizotinib in a Non-Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38.	1.1	87

#	ARTICLE	IF	CITATIONS
19	Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 23-29.	2.0	87
20	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1608-1618.	1.1	78
21	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	1.1	77
22	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4.	1.1	76
23	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 446-454.	6.4	75
24	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019, 51, 502-509.	3.0	74
25	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	4.1	72
26	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1640-1650.	1.1	64
27	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. <i>Oncotarget</i> , 2015, 6, 43731-43742.	1.8	63
28	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456.	1.6	61
29	Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. <i>Cancer Medicine</i> , 2015, 4, 1196-1204.	2.8	60
30	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	1.1	60
31	MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	2.9	57
32	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1338-1350.	3.0	56
33	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	3.1	56
34	Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e190339.	7.1	55
35	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <i>Cancer Research and Treatment</i> , 2019, 51, 737-747.	3.0	53
36	Regulatory (FoxP3 <sup>+</sup> ) T cells and TGF- $\beta$ 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	3.3	52

#	ARTICLE	IF	CITATIONS
37	Gene Expression Profiling of Breast Cancer Brain Metastasis. <i>Scientific Reports</i> , 2016, 6, 28623.	3.3	51
38	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 258-263.	1.1	50
39	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 14803-14813.	1.8	49
40	Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. <i>Cancer Research and Treatment</i> , 2019, 51, 1400-1410.	3.0	49
41	Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1466768.	4.6	48
42	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 591-598.	2.3	47
43	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
44	Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 389-394.	2.1	45
45	Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 118.	1.8	45
46	The relationship between nuclear factor (NF)- $\kappa$ B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. <i>Scientific Reports</i> , 2016, 6, 31804.	3.3	44
47	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	1.8	44
48	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43
49	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1106-1112.	1.1	42
50	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631.	3.0	40
51	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016, 33, 97.	2.5	39
52	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2016, 16, 138.	2.6	39
53	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92.	2.0	39
54	ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-III A anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8569-TPS8569.	1.6	39

#	ARTICLE	IF	CITATIONS
55	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	2.0	38
56	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>OncoImmunology</i> , 2020, 9, 1722023.	4.6	37
57	High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	4.1	37
58	Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1806-1813.	1.1	36
59	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	1.8	36
60	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	12.8	34
61	Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 475-489.	2.5	33
62	Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. <i>Journal of Pain Research</i> , 2017, Volume 10, 1963-1972.	2.0	33
63	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	2.8	33
64	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 698-705.	2.8	32
65	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 360-368.	2.6	32
66	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020, 20, 19.	1.4	32
67	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653.	6.4	31
68	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. <i>Lung Cancer</i> , 2013, 82, 455-460.	2.0	30
69	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264.	2.0	30
70	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016, 22, 2139-2145.	7.0	30
71	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e29-e31.	1.1	30
72	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	3.0	30

#	ARTICLE	IF	CITATIONS
73	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020, 9, 2352-2362.	2.8	29
74	A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014, 84, 51-55.	2.0	28
75	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e34-e36.	1.1	28
76	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158.	2.8	28
77	Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 67526-67537.	1.8	28
78	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016, 16, 5.	2.8	27
79	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 737-745.	2.5	27
80	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
81	Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and) Tj ETQq1 1 0.784314 rgBT /Overloc	2.0	26
82	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	5.1	26
83	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	4.1	26
84	Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. <i>Scientific Reports</i> , 2016, 6, 33035.	3.3	24
85	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1141-e1147.	2.4	24
86	First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3551-3551.	1.6	24
87	The NEXT-1 (Next generation pERsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	1.8	24
88	Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK-rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2022, 11, 2944-2956.	2.8	24
89	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
90	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 594-601.	1.3	23

#	ARTICLE	IF	CITATIONS
91	Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. <i>Oncotarget</i> , 2017, 8, 27997-28007.	1.8	23
92	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908.	1.1	23
93	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 22-27.	2.0	22
94	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. <i>Cancer</i> , 2020, 126, 4002-4012.	4.1	22
95	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 69-78.	1.1	21
96	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	1.8	21
97	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. <i>Radiation Oncology Journal</i> , 2013, 31, 222.	1.5	21
98	Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015, 125, 331-338.	2.9	20
99	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	2.5	19
100	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803.	1.4	19
101	Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. <i>Palliative and Supportive Care</i> , 2018, 16, 137-145.	1.0	19
102	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9075-9075.	1.6	19
103	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. <i>SpringerPlus</i> , 2013, 2, 136.	1.2	18
104	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018, 13, e0194730.	2.5	18
105	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	2.5	18
106	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8008-8008.	1.6	18
107	Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. <i>Cancer Research and Treatment</i> , 2019, 51, 727-736.	3.0	18
108	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17



#	ARTICLE	IF	CITATIONS
109	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542.	1.6	17
110	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 292-300.	3.0	17
111	Efficacy and Safety of Lorlatinib in Korean Non-“Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019, 20, 215-221.	2.6	16
112	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102415.	3.3	16
113	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
114	Alectinib versus crizotinib in treatment-naïve advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9008-LBA9008.	1.6	16
115	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. <i>European Journal of Immunology</i> , 2021, 51, 956-964.	2.9	15
116	An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9050-9050.	1.6	15
117	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 148-156.	1.1	15
118	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 408-412.	3.0	15
119	PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. <i>Journal of Breast Cancer</i> , 2018, 21, 382.	1.9	14
120	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1749-1758.	2.8	14
121	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. <i>Frontiers in Oncology</i> , 2021, 11, 596364.	2.8	14
122	Development and Validation of Digital Health Technology Literacy Assessment Questionnaire. <i>Journal of Medical Systems</i> , 2022, 46, 13.	3.6	14
123	AZD9291 overcomes T790M-mediated resistance through degradation of EGFR L858R/T790M in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016, 34, 407-415.	2.6	13
124	Clinical features and prognosis of breast cancer with gastric metastasis. <i>Oncology Letters</i> , 2019, 17, 1833-1841.	1.8	13
125	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
126	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 1.	1.5	13



#	ARTICLE	IF	CITATIONS
127	Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. <i>Oncologist</i> , 2015, 20, 1440-1447.	3.7	12
128	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 329-336.	1.1	12
129	Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018, 117, 7-13.	2.0	12
130	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018, 124, 293-297.	2.0	12
131	Sedation for terminally ill cancer patients. <i>Medicine (United States)</i> , 2019, 98, e14278.	1.0	12
132	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS596-TPS596.	1.6	12
133	Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Research and Treatment</i> , 2020, 52, 907-916.	3.0	12
134	&lt;i>EGFR&/i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with &lt;i>EGFR&/i> T790M Mutation. <i>Cancer Research and Treatment</i> , 2020, 52, 1288-1290.	3.0	12
135	Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. <i>Oncologist</i> , 2014, 19, 702-703.	3.7	11
136	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. <i>Journal of Breast Cancer</i> , 2016, 19, 169.	1.9	11
137	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020, 10, 13231.	3.3	11
138	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 5260.	3.7	11
139	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	2.4	10
140	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 1382-1388.	3.0	10
141	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 617-625.	2.5	10
142	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
143	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	2.0	10
144	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With <i>MET</i> Exon 14 Skipping. <i>In Vivo</i> , 2020, 34, 1399-1406.	1.3	10

#	ARTICLE	IF	CITATIONS
145	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 747-757.	2.5	10
146	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8514-8514.	1.6	10
147	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 30929-30938.	1.8	10
148	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726.	3.0	10
149	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020, 20, e48.	3.6	10
150	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53.	2.8	10
151	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. <i>Clinical Breast Cancer</i> , 2015, 15, 512-518.	2.4	9
152	Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 159-166.	1.1	9
153	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 769-776.	3.0	9
154	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425.	0.8	9
155	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. <i>Journal of Breast Cancer</i> , 2018, 21, 206.	1.9	8
156	Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. <i>BMC Cancer</i> , 2019, 19, 84.	2.6	8
157	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1935-1942.	1.8	8
158	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	3.4	8
159	Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care;) <i>Tj ETQq1 1 0.784314ogBT /Overlock 10</i>		
160	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281.	1.2	8
161	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. <i>Cancer Research and Treatment</i> , 2022, , .	3.0	8
162	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. <i>Oncotarget</i> , 2015, 6, 24499-24510.	1.8	7

#	ARTICLE	IF	CITATIONS
163	A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors. <i>BMC Cancer</i> , 2018, 18, 45.	2.6	7
164	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018, 119, 36-41.	2.0	7
165	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
166	Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors. <i>Cancer Research and Treatment</i> , 2022, 54, 10-19.	3.0	7
167	The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 8693-8706.	1.8	7
168	Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 645-652.	3.0	7
169	A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians. <i>Cancer Research and Treatment</i> , 2014, 46, 131-140.	3.0	7
170	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?. <i>Frontiers in Oncology</i> , 2021, 11, 759150.	2.8	7
171	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328.	7.0	7
172	Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321.	7.0	7
173	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. <i>Clinical Breast Cancer</i> , 2015, 15, e197-e204.	2.4	6
174	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. <i>PLoS ONE</i> , 2016, 11, e0163254.	2.5	6
175	Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2051-2052.	1.1	6
176	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. <i>Biology</i> , 2020, 9, 326.	2.8	6
177	Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 659-668.	2.2	6
178	Alectinib versus crizotinib in treatment-naïve advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9008-LBA9008.	1.6	6
179	Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma. <i>Cancer Research and Treatment</i> , 2013, 45, 343-348.	3.0	6
180	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021, 159, 167-173.	2.8	6

#	ARTICLE	IF	CITATIONS
181	Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. <i>Cancers</i> , 2021, 13, 5835.	3.7	6
182	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220.	2.8	6
183	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 200.	6.2	6
184	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 50.	1.9	5
185	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016, 100, 24-29.	2.0	5
186	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 933-942.	3.1	5
187	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	2.6	5
188	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8562-8562.	1.6	5
189	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChelN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7500-7500.	1.6	5
190	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9072-9072.	1.6	5
191	Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9603-9603.	1.6	5
192	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	2.0	4
193	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186.	1.4	4
194	Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016, 96, 48-51.	2.0	4
195	Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 225-231.	1.8	4
196	Discomfort related to Peripherally Inserted Central Catheters in Cancer Patient. <i>Asian Oncology Nursing</i> , 2017, 17, 229.	0.6	4
197	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 878-888.	2.8	4
198	Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 585-585.	1.6	4

#	ARTICLE	IF	CITATIONS
199	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 765-773.	3.0	4
200	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021, 10, 3865-3874.	2.8	4
201	Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. <i>Journal of Thoracic Disease</i> , 2020, 12, 4612-4622.	1.4	4
202	Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study. <i>Scientific Reports</i> , 2022, 12, 5489.	3.3	4
203	Micropapillary Mucinous Adenocarcinoma of the Lung: A Brief Case Report. <i>Korean Journal of Pathology</i> , 2013, 47, 603.	1.3	3
204	The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). <i>PLoS ONE</i> , 2016, 11, e0149432.	2.5	3
205	Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2202-2207.	1.1	3
206	Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 12215.	3.3	3
207	Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT). <i>Supportive Care in Cancer</i> , 2020, 28, 1829-1837.	2.2	3
208	Patient-Reported Outcomes Measurement Information System: Translation and Linguistic Validation of Six Profile Domains for Korean Adults. <i>Journal of Korean Medical Science</i> , 2021, 36, e212.	2.5	3
209	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. <i>Journal of Clinical Oncology</i> , 2015, 33, 8078-8078.	1.6	3
210	Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e60-e67.	1.3	2
211	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1059-1067.	4.1	2
212	Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea. <i>Diagnostics</i> , 2021, 11, 370.	2.6	2
213	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG) Tj ETQq1 1 0.784314 rgBT <sub>2</sub> /Overlo	1.6	2
214	Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype. <i>Clinical Breast Cancer</i> , 2021, 21, e402-e414.	2.4	2
215	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119). <i>Journal of Clinical Oncology</i> , 2012, 30, 1003-1003.	1.6	2
216	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results. <i>Journal of Clinical Oncology</i> , 2018, 36, 9033-9033.	1.6	2

#	ARTICLE	IF	CITATIONS
217	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 10.	0.1	2
218	Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. <i>Cancer Research and Treatment</i> , 2017, 49, 880-889.	3.0	2
219	ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 265.	2.6	2
220	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. <i>Oncology</i> , 2022, 100, 228-237.	1.9	2
221	Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-04-P2-13-04.	0.9	2
222	The Clinical Guidelines for Myelodysplastic Syndrome. <i>The Korean Journal of Hematology</i> , 2007, 42, 71.	0.7	1
223	Limited Supraclavicular Radiation Field in Breast Cancer With 10 Positive Axillary Lymph Nodes. <i>Clinical Breast Cancer</i> , 2016, 16, e15-e21.	2.4	1
224	The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 653243.	2.8	1
225	A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. <i>Journal of Clinical Oncology</i> , 2015, 33, 8086-8086.	1.6	1
226	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 9094-9094.	1.6	1
227	The Prognostic Utility of the Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) Score for Hemato-Oncology Patients Admitted to the Intensive Care Unit. <i>The Korean Journal of Critical Care Medicine</i> , 2009, 24, 4.	0.2	1
228	Bone Marrow Cellularity Is a Single Most Important Independent Prognostic Factor In AML Patients with t(8;21). <i>Blood</i> , 2010, 116, 1707-1707.	1.4	1
229	Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma. <i>Cancer Research and Treatment</i> , 2014, 46, 200-203.	3.0	1
230	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). <i>Journal of Clinical Oncology</i> , 2016, 34, e20507-e20507.	1.6	1
231	The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing. <i>Journal of Clinical Oncology</i> , 2017, 35, e20584-e20584.	1.6	1
232	Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 858-860.	1.2	1
233	Generation and Qualification of Functionally Active Leukemia-derived DCs from Malignant Blasts in Acute Leukemia. <i>The Korean Journal of Hematology</i> , 2007, 42, 264.	0.7	0
234	Reply to Y.H. Kim and M. Mishima. <i>Journal of Clinical Oncology</i> , 2016, 34, 768-768.	1.6	0



#	ARTICLE	IF	CITATIONS
235	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. <i>Cancers</i> , 2020, 12, 1306.	3.7	0
236	Abstract PS10-38: Real World Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience. , 2021, , .		0
237	Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea. , 2021, , .		0
238	Long-term Survival in Non-“Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. <i>Cancer Research and Treatment</i> , 2022, 54, 150-156.	3.0	0
239	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. <i>Blood</i> , 2005, 106, 5415-5415.	1.4	0
240	Preliminary Results of a Prospective Multicenter Phase III Trial Comparing High-Dose and Standard-Dose Daunorubicin for Induction of Complete Remission (CR) in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1833-1833.	1.4	0
241	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7104-7104.	1.6	0
242	Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19051-e19051.	1.6	0
243	Experience and difficulties from working with cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20603-e20603.	1.6	0
244	Cancer pain management practices and their impact on quality of life for Asian cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6531-6531.	1.6	0
245	Contribution of clinical trials to improved clinical outcomes for patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e12596-e12596.	1.6	0
246	Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14118-e14118.	1.6	0
247	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjvant docetaxel chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10108-10108.	1.6	0
248	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21136-e21136.	1.6	0
249	Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24115-e24115.	1.6	0
250	Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2564-2564.	1.6	0
251	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq1 1 0.784314ogBT /Over		0
252	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. <i>Cancer Research</i> , 2022, 82, P3-13-08-P3-13-08.	0.9	0

#	ARTICLE	IF	CITATIONS
253	The 10-year journey of non-“small cell lung cancer: A real-world experience.. Journal of Clinical Oncology, 2022, 40, 9133-9133.	1.6	0
254	Exploratory analysis using cfDNA-based fragmentomics to predict disease recurrence in limited disease small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 8569-8569.	1.6	0